Survival rate after mid-stage surgery for medullary thyroid cancer is related to the surgery method, physical condition and so on. Generally speaking, the 10-year survival rate of medullary thyroid cancer patients with metastasis is only 40%; while the 10-year survival rate of medullary thyroid cancer patients without metastasis can reach 70%. Medullary thyroid carcinoma is highly malignant, second only to undifferentiated thyroid cancer. Medullary carcinoma in the middle stage may have metastasis, but it can be cured with early surgery and active radiotherapy and chemotherapy. Thanks to the latest targeted drugs, its recurrence rate can also be greatly reduced. It is worth noting that if the patient does not finish the treatment as early as possible, the disease is prolonged, distant metastasis occurs, the difficulty of surgery is increased, and the drug treatment is not complete, the survival period will also be greatly reduced. Therefore, patients diagnosed with intermediate stage medullary thyroid carcinoma should receive treatment as early as possible and be treated with iodine 131 routinely after surgery to maximize the survival period.